Literature DB >> 17942545

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Ann M Leen1, Anne Christin, Mariam Khalil, Heidi Weiss, Adrian P Gee, Malcolm K Brenner, Helen E Heslop, Cliona M Rooney, Catherine M Bollard.   

Abstract

Adenoviral infections in the immunocompromised host are associated with significant morbidity and mortality. Although the adoptive transfer of adenovirus-specific T cells may prevent and treat such infections, the T-cell immune response to the multiplicity of adenovirus serotypes and subspecies that infect humans has not been well characterized, impeding the development of such approaches. We have, therefore, analyzed the specificities of T-cell responses to the viral capsid hexon antigen, since this structure is highly conserved in human pathogens. We screened 25 human cytotoxic T-cell lines with adenovirus specificity to extensively characterize their responses to adenoviral hexon and to identify a panel of novel CD4(+) and CD8(+) T-cell epitopes. Using a peptide library spanning the entire sequence of the hexon protein, we confirmed the responsiveness of these cytotoxic T-cell lines to seven peptides described previously and also identified 33 new CD4- or CD8-restricted hexon epitopes. Importantly, the majority of these epitopes were shared among different adenovirus subspecies, suggesting that T cells with such specificities could recognize and be protective against multiple serotypes, simplifying the task of effective adoptive transfer or vaccine-based immunotherapy for treating infection by this virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942545      PMCID: PMC2224388          DOI: 10.1128/JVI.01689-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Authors:  Ann M Leen; Uluhan Sili; Barbara Savoldo; Alan M Jewell; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

2.  The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope.

Authors:  Melanie Olive; Laurence Eisenlohr; Neal Flomenberg; Susan Hsu; Phyllis Flomenberg
Journal:  Hum Gene Ther       Date:  2002-07-01       Impact factor: 5.695

3.  Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults.

Authors:  M Olive; L C Eisenlohr; P Flomenberg
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

4.  Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.

Authors:  Yamina Hamel; Neil Blake; Susanne Gabrielsson; Tracey Haigh; Karin Jooss; Chantal Martinache; Sophie Caillat-Zucman; Alan B Rickinson; Salima Hacein-Bey; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Hum Gene Ther       Date:  2002-05-01       Impact factor: 5.695

5.  Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods.

Authors:  John J Rux; Paula R Kuser; Roger M Burnett
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.

Authors:  Tobias Feuchtinger; Peter Lang; Klaus Hamprecht; Michael Schumm; Johann Greil; Gerhard Jahn; Dietrich Niethammer; Hermann Einsele
Journal:  Exp Hematol       Date:  2004-03       Impact factor: 3.084

7.  Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele.

Authors:  J Tang; M Olive; K Champagne; N Flomenberg; L Eisenlohr; S Hsu; P Flomenberg
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

Review 8.  The impact of adenovirus infection on the immunocompromised host.

Authors:  Tsoline Kojaoghlanian; Phyllis Flomenberg; Marshall S Horwitz
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

9.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

Authors:  E A Walter; P D Greenberg; M J Gilbert; R J Finch; K S Watanabe; E D Thomas; S R Riddell
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

10.  T cells compete for access to antigen-bearing antigen-presenting cells.

Authors:  R M Kedl; W A Rees; D A Hildeman; B Schaefer; T Mitchell; J Kappler; P Marrack
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  66 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

2.  Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Authors:  Juan F Vera; Lara J Brenner; Ulrike Gerdemann; Minhtran C Ngo; Uluhan Sili; Hao Liu; John Wilson; Gianpietro Dotti; Helen E Heslop; Ann M Leen; Cliona M Rooney
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

Review 3.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 4.  Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.

Authors:  Justin L Madrigal; Roberta Stilhano; Eduardo A Silva
Journal:  Tissue Eng Part B Rev       Date:  2017-03-10       Impact factor: 6.389

5.  Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Authors:  Yeon Joo Lee; Dick Chung; Kun Xiao; Esperanza B Papadopoulos; Juliet N Barker; Trudy N Small; Sergio A Giralt; Junting Zheng; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

6.  Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

Authors:  Lauren P McLaughlin; Haili Lang; Elizabeth Williams; Kaylor E Wright; Allison Powell; Conrad R Cruz; Anamaris M Colberg-Poley; Cecilia Barese; Patrick J Hanley; Catherine M Bollard; Michael D Keller
Journal:  Cytotherapy       Date:  2016-09-28       Impact factor: 5.414

Review 7.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

8.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

Review 10.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.